Which drugs in other areas go off patent, and when?
7 blockbuster drugs in other areas with about $33.0B in 2025 worldwide sales lose US exclusivity between 2025 and 2037, led by Trikafta (Vertex, $10.3B). 2 lose it in 2025 or 2026; the biggest single year is 2037, with $10.3B.
2025 worldwide sales of each drug, placed in the year its first US generic or biosimilar can launch. Select a year for every drug going off patent that year.
| Drug | Company | US LOE | 2025 sales | Date basis | US copies | Medicare price |
|---|---|---|---|---|---|---|
| Prolia | Amgen | 2025 | $4.4B | Biosimilars launched | Copies on the US market | – |
| Opsumit | Johnson & Johnson | 2026 | $2.3B | Generics launched | Copies on the US market | – |
| Trelegy | GSK | 2027 | ≈$3.9B | Patent-expiry estimate | No US filing found | 2027 · −73% |
| Reblozyl | Bristol Myers Squibb | 2031 | $2.3B | Company guidance | No US filing found | – |
| Vabysmo | Roche | 2034 | ≈$4.9B | Patent-expiry estimate | No US filing found | – |
| Ultomiris | AstraZeneca | 2035 | $4.7B | Company guidance | No US filing found | – |
| Trikafta | Vertex | 2037 | $10.3B | Patent-expiry estimate | No US filing found | – |
Sorted by the year US exclusivity ends. Each drug's page has the sources.
| Company | Drugs | 2025 revenue from them | Share of company |
|---|---|---|---|
| Vertex | Trikafta | $10.3B | 86% |
| Roche | Vabysmo | ≈$4.9B | 6.7% |
| AstraZeneca | Ultomiris | $4.7B | 8% |
| Amgen | Prolia | $4.4B | 12% |
| GSK | Trelegy | ≈$3.9B | 9.1% |
| Johnson & Johnson | Opsumit | $2.3B | 2.5% |
| Bristol Myers Squibb | Reblozyl | $2.3B | 4.8% |
For shared drugs, each company is credited with the revenue it reports, so nothing is counted twice. Share is of the company's total 2025 revenue.
Trelegy (2027, −73%) was selected for Medicare price negotiation. See every negotiated Medicare price →